454 related articles for article (PubMed ID: 16939632)
1. C-reactive protein (CRP)-lowering agents.
Prasad K
Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
[TBL] [Abstract][Full Text] [Related]
2. Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure.
Joynt KE; Gattis WA; Hasselblad V; Fuzaylov SY; Serebruany VL; Gurbel PA; Gaulden LH; Felker GM; Whellan DJ; O'Connor CM
Am J Cardiol; 2004 Mar; 93(6):783-5. PubMed ID: 15019895
[TBL] [Abstract][Full Text] [Related]
3. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
Patrick L; Uzick M
Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
[TBL] [Abstract][Full Text] [Related]
5. Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction.
Quinaglia e Silva JC; Munhoz DB; Morato TN; Gurgel A; Macedo AC; Sever P; Sposito AC;
Am J Cardiol; 2009 Feb; 103(4):461-3. PubMed ID: 19195502
[TBL] [Abstract][Full Text] [Related]
6. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
[TBL] [Abstract][Full Text] [Related]
7. Role of C-reactive protein in cardiovascular disease.
Backes JM; Howard PA; Moriarty PM
Ann Pharmacother; 2004 Jan; 38(1):110-8. PubMed ID: 14742804
[TBL] [Abstract][Full Text] [Related]
8. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin.
Hu WL; Qiao SB; Li JJ
Cytokine; 2007 Dec; 40(3):201-6. PubMed ID: 18023360
[TBL] [Abstract][Full Text] [Related]
9. [The non-lipid effects of statins].
Paragh G; Márk L; Katona E
Orv Hetil; 2004 Sep; 145(37):1903-10. PubMed ID: 15493621
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein, antiinflammatory drugs, and quality of life in diabetes.
Cummings DM; King DE; Mainous AG
Ann Pharmacother; 2003 Nov; 37(11):1593-7. PubMed ID: 14565804
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
Kinlay S
J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355
[TBL] [Abstract][Full Text] [Related]
12. Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria.
van der Harst P; Asselbergs FW; Hillege HL; Voors AA; van Veldhuisen DJ; van Gilst WH;
Am J Cardiol; 2008 Jul; 102(2):223-5. PubMed ID: 18602526
[TBL] [Abstract][Full Text] [Related]
13. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
[TBL] [Abstract][Full Text] [Related]
14. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Arnaud C; Burger F; Steffens S; Veillard NR; Nguyen TH; Trono D; Mach F
Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1231-6. PubMed ID: 15790934
[TBL] [Abstract][Full Text] [Related]
15. Effects of losartan and enalapril on high-sensitivity C-reactive protein and total antioxidant in renal transplant recipients with Renin-Angiotensin system polymorphisms.
Argani H; Ghorbanihaghjo A; Aghaeishahsavari M; Noroozianavval M; Rashtchizadeh N; Veisi P; Safa J; Abediazar S
Transplant Proc; 2008; 40(1):16-21. PubMed ID: 18261537
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home.
Joseph J; Koka M; Aronow WS
J Am Med Dir Assoc; 2008 Feb; 9(2):124-7. PubMed ID: 18261706
[TBL] [Abstract][Full Text] [Related]
17. Does reversal of oxidative stress and inflammation provide vascular protection?
Koh KK; Oh PC; Quon MJ
Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis.
Rosenau BJ; Costenbader KH; Schur PH
Vasc Med; 2008 Feb; 13(1):25-8. PubMed ID: 18372435
[TBL] [Abstract][Full Text] [Related]
19. Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients.
Kim CJ
J Cardiovasc Pharmacol; 2006 Jun; 47(6):758-63. PubMed ID: 16810076
[TBL] [Abstract][Full Text] [Related]
20. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Field KM
Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
